Pfizer vaccine: an immunologist explains

Pfizer and BioNTech have concluded the Phase 3 trial of their coronavirus vaccine. The results appear to show an efficacy rate of 95%, and the developers hope to win FDA approval as soon as possible. This vaccine - a promising hope for many - works via a new methiod that’s never been tried before in humans. Chris Smith asked Cambridge University immunologist Clare Bryant for her reaction...